Published in J Antimicrob Chemother on December 07, 2011
Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog (2013) 2.02
Prospects for treatment of latent HIV. Clin Pharmacol Ther (2012) 1.91
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog (2014) 1.88
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest (2015) 1.76
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
Developing strategies for HIV-1 eradication. Trends Immunol (2012) 1.38
Combined approaches for HIV cure. Curr Opin HIV AIDS (2013) 1.23
HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS (2013) 1.15
A hardwired HIV latency program. Cell (2015) 1.08
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nat Protoc (2014) 0.86
HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol (2016) 0.83
Substituted oxines inhibit endothelial cell proliferation and angiogenesis. Org Biomol Chem (2012) 0.81
Progress and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacol Sin (2015) 0.80
Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency. PLoS One (2015) 0.78
Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies. PLoS One (2014) 0.76
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr (1996) 4.62
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. Gigascience (2012) 20.89
The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Ancient human genome sequence of an extinct Palaeo-Eskimo. Nature (2010) 7.51
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med (2005) 6.02
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med (2003) 5.14
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Assemblathon 2: evaluating de novo methods of genome assembly in three vertebrate species. Gigascience (2013) 4.11
Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med (2004) 4.06
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell (2008) 3.84
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol (2010) 3.44
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28
Practice patterns in choice of left double-lumen tube size for thoracic surgery. Anesth Analg (2008) 3.25
The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med (2007) 3.20
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13
Curated genome annotation of Oryza sativa ssp. japonica and comparative genome analysis with Arabidopsis thaliana. Genome Res (2007) 3.13
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00
Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol (2005) 2.99
Competing autonomic mechanisms precede the onset of postoperative atrial fibrillation. J Am Coll Cardiol (2003) 2.92
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity (2010) 2.82
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov (2011) 2.77
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci (2007) 2.75
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol (2006) 2.72
Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol (2007) 2.71
Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr (2002) 2.70
The multifactorial nature of HIV-1 latency. Trends Mol Med (2004) 2.68
Eukaryotic initiation factor 2alpha-independent pathway of stress granule induction by the natural product pateamine A. J Biol Chem (2006) 2.67
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA (2007) 2.59
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol (2005) 2.55
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell (2010) 2.54
MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci U S A (2010) 2.53
Exome sequencing identifies ZNF644 mutations in high myopia. PLoS Genet (2011) 2.52
Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS (2005) 2.48
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst (2012) 2.47
Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2008) 2.44
Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother (2003) 2.44
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A (2009) 2.33
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2005) 2.32
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Synthesis, molecular modeling, and biological evaluation of cinnamic acid metronidazole ester derivatives as novel anticancer agents. Bioorg Med Chem (2010) 2.25
RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol Cell Biol (2007) 2.20
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet (2003) 2.19
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS (2014) 2.18
Dual HIV-1 infection associated with rapid disease progression. Lancet (2004) 2.17
Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell (2005) 2.17
Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol (2013) 2.14
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol (2009) 2.10
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe (2008) 2.08